- Home
- PGEN vs ATAI Comparison
PGEN vs ATAI Comparison
Compare PGEN & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGEN | ATAI |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PGEN | ATAI |
|---|---|---|
| Price | $3.10 | $3.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $7.67 | ★ $15.57 |
| AVG Volume (30 Days) | 3.4M | ★ 4.7M |
| Earning Date | 03-25-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $230,981,000.00 | $308,000.00 |
| Revenue This Year | $342.78 | N/A |
| Revenue Next Year | $478.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.11 | $1.15 |
| 52 Week High | $5.47 | $6.73 |
Technical Indicators
Market Signals| Indicator | PGEN | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 33.67 | 45.73 |
| Support Level | $2.99 | $3.48 |
| Resistance Level | $5.10 | $4.30 |
| Average True Range (ATR) | 0.17 | 0.22 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 10.83 | 28.93 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.